Navigation Links
AMRI Signs Agreement for Exclusive License of its Tubulin Inhibitor Program for Cancer
Date:2/11/2013

om our past R&D investments. As we have stated previously, we will continue to pursue strategic opportunities to enable AMRI to advance the clinical development of our other compounds and programs to create near- and long-term value for the company."

Barry A. Berkowitz , Ph.D., President and CEO of Bessor said, "In AMRI's work to date, ALB 109564(a) has shown significant promise as a next generation tubulin inhibitor for the treatment of cancer. Through our integrated network of drug development and clinical experts and the flexible structure afforded by Chai, we plan to advance the clinical program to further define the compound's potential.  ALB 109564(a) is one of several translational projects in Bessor's growing portfolio that it is advancing to key value points."

AMRI has built a strong initial program around ALB 109564(a), providing an early indication that it may offer clinically relevant activity distinct from other tubulin inhibitors. This proprietary program, as well as AMRI's other available pipeline programs in the therapeutic areas of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), cognitive impairment and schizophrenia, were each created with business strategies aimed at differentiating them from existing standards of care.

About ALB 109564(a) and Oncology

ALB 109564(a) is a novel analog from an established and marketed class of tubulin inhibitors, which is designed to kill cancer cells by preventing cell mitosis. The discovery of ALB 109564(a) leveraged AMRI's unique biocatalysis technology platform, natural products chemistry expertise, and high potency development capabilities. ALB 109564(a) has significant benefits compared with existing tubulin inhibitors in the same class. AMRI's Phase I study of ALB 109564(a) involved intravenous administration of ALB 109564(a) to cancer patients with advanced solid tumors. The study was designed to evaluate the compound's sa
'/>"/>

SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Deborah Morosini, MD Pathologist and Patient Advocate Signs on as Medical Director and Advisory Board Member of Store-A-Tooth™ Dental Stem Cell Banking
2. Trade Show Display Co. GLM Displays Redesigns Blog
3. Touch Medical Media Splits From Touch Briefings, Launches a Series of Cutting Edge, Free to Access, Educational Resources and Signs an Updated Media Partnership With ECCO, The European CanCer Organisation Representing 60,000 Oncology Professionals
4. MakeSigns.com Announces New Tri-Fold Scientific Poster Service
5. Florida-Based Team Gemini Signs Recycling Facility Agreement with Solid Waste Authority of Central Ohio
6. Ben-Gurion University develops side-illuminated ultra-efficient solar cell designs
7. Bluechiip Signs Strategic Partnership with Gentris Corporation
8. BioPower Operations Corporation Announces that FTZ Exchange Signs Strategic Alliance with Capacity 360, LLC and Tom Settineri
9. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
10. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
11. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... The first product launch from start-up ... to robotics. What sets Droidles completely apart from other ... allows them to communicate, share code with each other ... , “The invention is the system,” said Hurley Research ... life of their own, both physically and on the ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The prestigious ... of Congress was recently awarded to Juliana Hillis and ... MA, for their project, “From an Egg, Everything: America’s ... 3,000 final entries for the National History Day program ... 300 historians and educators in Washington, D.C. , The ...
(Date:7/29/2014)... July 29, 2014 White papers ... and cloud based eClinical technologies, have been published by ... These follow a long line of white papers by ... including Life Science Leader, Pharmaceutical Online, and OpenHealthNews. , ... a paper by CTO Marc Desgrousilliers, 'The Five ...
(Date:7/29/2014)... July 29, 2014 ... (LBS) zur Erfassung biologischer Daten in Verbindung ... und patentiert. Das LBS nimmt gleichzeitig mehrere ... des Patienten und sucht erhöhte biologische Aktivitäten ... Potenzial, die Entdeckung und Entwicklung neuer Medikamente ...
Breaking Biology Technology:Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4
... only Web-based solution for managing compliance and regulated content throughout ... , SAN DIEGO, June 22 Drug ... Virtify, Inc. , the market leader in enterprise ... upcoming release of its Virtx integrated software suite, an end-to-end, ...
... alternative to Singulair and Zicam - The ALCAT Test , ... FDA knocked the wind out of asthmatics by requesting the ... drug, to upgrade their warning against psychotic side effects. Further ... also last week announced warnings that the drug may cause ...
... , , SINGAPORE, June 22 Globally, the largest ... achieve a reduction in CO2 emissions by 8.0 percent between 2008 ... 5.75 percent bio-fuels of all transportation fuel by December 2010 and ... market, it is witnessing rapid growth in terms of both new ...
Cached Biology Technology:Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 2Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 3Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 4Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 5Knocking the Wind Out of Asthmatics: Help from Hippocrates 2Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 2Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 3Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 4
(Date:7/28/2014)... of Medicine have pinpointed a mechanism in part of the ... blood, linking it to both type 1 and type 2 ... of Proceedings of the National Academies of Sciences . ... located in a part of the hypothalamus known as the ... that control glucose levels in the blood," said lead author ...
(Date:7/28/2014)... the top 10 U.S. cities that have seen an ... as frequent road closures, overwhelmed storm drains and compromised ... NOAA technical report. , This nuisance flooding, caused by ... coasts, between 300 and 925 percent since the 1960s. ... Frequency Changes around the United States, also finds Annapolis ...
(Date:7/28/2014)... has identified areas of the Earth that are high ... , Europe is particularly vulnerable, as it has the ... cent, of any continent in ,refugia, areas of ... conditions remain relatively constant during times of great environmental ... mostly in Scandinavia and Scotland. , The biggest ...
Breaking Biology News(10 mins):Glucose 'control switch' in the brain key to both types of diabetes 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2
... TORONTO, ON A team of University of Toronto chemists ... quantum biology, observing quantum mechanics at work in photosynthesis in ... speculation that nature may be using quantum mechanical practices," says ... published this week in Nature . "Our latest ...
... that glaciers in the Himalayan mountains are thinning is ... examine and quantify the causes. Lawrence Berkeley National Laboratory ... of the most commonly blamed culpritgreenhouse gases, such as ... be causing the melting. Menon and her collaborators found ...
... For Immediate Release A team of scientists at ... on novel binding sites for an enzyme used by the ... discovery lays the foundation for the development of a new ... strains of the disease, and slow the evolution of drug ...
Cached Biology News:Scientists find quantum mechanics at work in photosynthesis 2Black carbon a significant factor in melting of Himalayan glaciers 2Black carbon a significant factor in melting of Himalayan glaciers 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 2Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 4Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 5
Sheep polyclonal to Streptomycin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule: Streptomycin conjugated to BSA....
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Biology Products: